Randomized double-blind Phase II trial of exemestane (Aromasin) plus dasatinib vs exemestane plus placebo in advanced ER+ breast cancer after disease progression on a non steroidal aromatase inhibitor (NSAI)

  • Rea, Daniel (Principal Investigator)

Project Details

Short titleRandomized double-blind Phase II trial of exemestane (Aromasin) plus dasatinib vs exemestane plus placebo in advanced ER+ breast cancer after disease progression on a non steroidal aromatase inhibitor (NSAI)
StatusFinished
Effective start/end date1/12/09 → 31/12/13

Funding

  • Sandwell & West Birmingham Hospitals